Axsome Therapeutics AXSM Accrued Liabilities & Other
Accrued Liabilities & Other at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's accrued liabilities & other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's accrued liabilities & other?
- Axsome Therapeutics (AXSM) reported accrued liabilities & other of $250.73M in Q1 2026.
- How has Axsome Therapeutics's accrued liabilities & other changed year-over-year?
- Axsome Therapeutics's accrued liabilities & other increased by 68.1% year-over-year, from $149.2M to $250.73M.
- What is the long-term trend for Axsome Therapeutics's accrued liabilities & other?
- Over 5 years (2020 to 2025), Axsome Therapeutics's accrued liabilities & other has grown at a 92.9% compound annual growth rate (CAGR), from $8.71M to $232.85M.
- What does accrued liabilities & other mean?
- Short-term expenses that have been incurred but not yet paid.
- How do you interpret accrued liabilities & other?
- Rising levels may reflect increased operational activity or headcount, whereas declining levels could indicate reduced operational overhead.
- How does accrued liabilities & other compare across companies?
- Common in all sectors; varies based on the scale of operations and administrative complexity.